China Medical System Holdings Limited (SGX:8A8)

Market Cap	5.47B
Revenue (ttm)	1.40B
Net Income (ttm)	293.38M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	18.65
Forward PE	16.10
Dividend	0.03 (1.15%)
Ex-Dividend Date	Sep 1, 2025

Volume	100
Average Volume	17,705
Open	2.380
Previous Close	2.430
Day's Range	2.380 - 2.380
52-Week Range	2.050 - 2.550
Beta	n/a
RSI	59.51
Earnings Date	Mar 15, 2026

About SGX:8A8

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,141
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 8A8

Financial Performance

In 2024, SGX:8A8's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.

Financial numbers in CNY